Noxopharm Ltd - Clinical Trial Program Commences - Will be testing NOX66 with Radiotherapy

Independent Investment Research

Independent Investment Research

This note is an update to our initiation note.  The company has commenced a comprehensive clinical trial program that will see the initiation of 7 clinical trials throughout 2017. The first clinical trial is underway which focuses on using NOX66 in conjunction with chemotherapy on patients with late-stage cancers. The company has determined through laboratory testing, that the behaviour of idronoxil in the body when delivered using the NOX66 formulation is vastly different than when idronoxil is delivered in other forms. The company has termed the form of idronoxil after being administered using the NOX66 formulation as “Idronoxil-C.”  After raising $6m for the IPO, the company has $3.6m remaining which is expected to be sufficient to cover the expenses of the clinical trial program. If meaningful clinical responses result from the clinical trials, the company will need to raise additional capital to undertake further trials and progress the development of the drug . Given the early stage of development of NOX66, an investment in the company is highly speculative. However, the company has taken significant steps in the development of NOX66 since we initiated coverage on the company in November 2016. 


MORE ON



Independent Investment Research, “IIR”, is an independent investment research house based in Australia and the United States. IIR specialises in independent research in small/ micro cap equities across sectors and managed investment ratings both...

I would like to

Only to be used for sending genuine email enquiries to the Contributor. Livewire Markets Pty Ltd reserves its right to take any legal or other appropriate action in relation to misuse of this service.

Personal Information Collection Statement
Your personal information will be passed to the Contributor and/or its authorised service provider to assist the Contributor to contact you about your investment enquiry. They are required not to use your information for any other purpose. Our privacy policy explains how we store personal information and how you may access, correct or complain about the handling of personal information.